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Marina Chatziioannou and Ioannis Papasotiriou*Abstract
Background: Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance,
whether developed or native, critically affects a treatment’s success. Single Cell Gel Εlectrophoresis - also known as a
comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet
assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer.
Results: We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin,
as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of
different cancer types.
Conclusion: The comet assay technique can provide reliable and quick results with minimum requirements and is
applicable to a wide variety of drugs.
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Personalized medicine requires that therapy should be
customized to individual patients, using genetic or other
information [1]. Prediction of response to chemotherapy
drugs is a major concern in cancer treatment [2]. Resistance
to chemotherapy agents may exist before, or develop dur-
ing, therapy [3]. Most techniques to predict response entail
analysis of expression of different genes [4]. However, fast,
reliable results are urgently needed; moreover, a drug’s
effect cannot always be predicted by measuring gene ex-
pression [5].
Single Cell Gel Electrophoresis (SCGE), also known as
comet assay can measure DNA damage in individual
eukaryotic cells. The principle of the comet assay is that
unfragmented DNA maintains a well-organized struc-
ture in the nucleus, but becomes disrupted when the cell
is damaged. It detects both single-strand and double-
strand breaks, and has a simple and inexpensive setup.
Comet assay is therefore a promising technique for* Correspondence: papasotiriou.ioannis@rgcc-genlab.com
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article, unless otherwise stated.predicting response to drugs that are affected by DNA
structure [6].
The present study evaluated the predictability of re-
sponse to widely used chemotherapy drug from comet
assay results in established human breast and colon can-
cer cell lines. We tested nitrogen-mustard alkylating
agents (melphalan, mechlorethamine) and doxorubicin
in breast cancer, and tested cisplatin in colon cancer cell
lines.Results and discussion
Analysis of results was based on percentages of DNA in
the comet “head” (amount of genetic material distrib-
uted in the nucleus) and in “tail” (amount of genetic
material distributed in the fragmented pieces). We ex-
amined ≥ 100 cells for each combination of cells and
drugs. With p set to be 0.05, we estimated the ranges of
DNA percentage in untreated and treated cells; where
these ranges overlapped, the cells were rejected. In the
MCF-7 and MDA-MB 231 cell lines, we clearly observed
functional activity for all drugs. The T47D cells showedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 DNA (%) presented in “head” and “tail” pre- and
post-incubation with doxorubicin in breast cancer cell lines
Control Cisplatin (1 μΜ)









in Head in Tail in Head in Tail
LoVo 83.55 ± 4.25 17.45 ± 4.12 89.28 ± 2.32 11.72 ± 2.29
HCT-15 78.58 ± 4.05 21.42 ± 4.05 92.35 ± 1.84 7.65 ± 1.83
HCT-116 84.92 ± 3.32 15.08 ± 3.27 92.50 ± 2.00 8.51 ± 1.88
HT55 82.17 ± 2.75 17.82 ± 2.75 90.60 ± 1.58 9.39 ± 1.51
Table 3 DNA (%) presented in “head” and “tail” pre- and
post-incubation with mechlorethamine in breast cancer
cell lines
Control Mechlorethamine ( 0.1 μM)









in Head in Tail in Head in Tail
MCF-7 71.03 ± 4.16 28.96 ± 4.16 83.71 ± 2.31 16.64 ± 2.26
MDA-MB 231 71.83 ± 2.49 28.16 ± 2.49 86.72 ± 1.52 13.43 ± 1.49
T47D 84.64 ± 2.77 84.64 ± 2.77 85.75 ± 2.11 14.24 ± 2.11
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not for mechlorethamine. All the colorectal cancer
cell lines except LoVo, were also successfully affected
(Tables 1, 2, 3 and 4; Figures 1, 2 and 3).
Comet visual scoring can be also calculated based on a
five-grade scale from 0 to 4. In a grade 4 comet cell, the
entire DNA is in the “tail”, while in grade 0 the entire
DNA is in “head”. These values given to comets can be
summarized and provide a quantitative measure for 100
cells on a scale from 0-400. These data are presented in
Figure 4. A high score means that the cells have been
damaged, and the most DNA is in “tail”. The decrease of
the score indicates unfragmented cells, therefore a posi-
tive effect by the particular drug. The higher the de-
crease, the greater the effect of the chemotherapeutic.
As it is presented in Figure 4, it is displayed little differ-
ence in the score of T47D under the treatment with
mechlorethamine. It is also observed that among the
colorectal cancer cell lines, cisplatin affects HCT-15
more than the others. Among MCF-7, MDA-MB 231
and T47D, the MCF-7 cell line is more affected by mel-
phalan and doxorubicin, while MDA-MB 231 is more
sensitive in mechlorethamine.
Breast cancer is the most lethal malignancy in women
[7]. Colorectal cancer is the second most common cause of
cancer in women, the third most common in men, and the
fourth most common cause of cancer death overall [8].
Management of cancer focuses on cure (achievable throughTable 2 DNA (%) presented in “head” and “tail” pre- and
post-incubation with melphalan in breast cancer cell lines
Control Melphalan (1 μM )









in Head in Tail in Head in Tail
MCF-7 66.43 ± 3.68 33.56 ± 3.68 83.96 ± 2.42 16.04 ± 2.35
MDA-MB 231 77.14 ± 2.98 22.85 ± 2.98 82.66 ± 2.33 17.34 ± 2.33
T47D 77.87 ± 2.60 22.12 ± 2.60 85.37 ± 1.93 14.62 ± 1.93surgery, chemotherapy or radiation) or palliation (an im-
portant consideration in incurable disease) [9,10]. Among
the variety of chemotherapeutic drugs against breast and
colorectal cancer are alkylating agents, which can prevent
DNA synthesis and RNA transcription by cross-linking
DNA; or by attaching to DNA bases, causing them to be
fragmented by repair enzymes. Alkylating agents can also
induce mispairing of nucleotides. As the mode of action
depends on the genetic structure, a means of detecting
changes in DNA structure is needed [11]. Nitrogen mus-
tards are non-specific cytotoxic chemotherapy agents,
and include cyclophosphamide, chlorambucil, uramustine,
ifosfamide, melphalan, bendamustine and mechloretha-
mine [12].
Melphalan in combination with other drugs, or as
monotherapy, is highly active in patients with advanced
breast cancer. It attaches an alkyl group to the 7′ nitro-
gen atom of the imidazole ring, in the DNA guanine
base. Melphalan has several side effects including leuco-
penia, thrombocytopenia and anemia, nausea, vomiting
and diarrhea [13]. Mechlorethamine also known as mus-
tine (HN2) is a derivative of mustard gas. It prevents
cell duplication by cross linking DNA; it is cell cycle
phase-nonspecific. It is used in humans and other mam-
mals. Overexposure can lead to leukopenia, anemia and
thrombocytopenia, while chromosomal abnormalities,
hepatotoxicity, neurotoxicity and cardiac irregularities
have been reported; both its hematologic and gastro-
intestinal side effects are usually dose-dependent. [14].Table 4 DNA (%) presented in “head” and “ tail ” pre- and
post-incubation with doxorubicin in breast cancer cell lines
Control Doxorubicin (1 μM)









in Head in Tail in Head in Tail
MCF-7 66.43 ± 3.68 33.56 ± 3.68 81.33 ± 2.67 19.17 ± 2.62
MDA-MB 231 77.14 ± 2.98 22.85 ± 2.98 83.93 ± 1.94 16.06 ± 1.94
T47D 77.87 ± 2.60 22.12 ± 2.60 83.17 ± 2.27 16.82 ± 2.27
Figure 1 Comet assay data for MDA-MB 231 cell line. A: Untreated cell line after alkaline lysis. B: The percentage of DNA in tail has been
reduced after incubation with doxorubicin. C: Data after incubation with melphalan. D: Treatment with mechlorethamine.
Figure 2 Comet assay data for cancer cell lines representing colorectal cancer. A: Control HCT-15 cell line without cisplatin. B: HCT-15 after
incubation with cisplatin. C: Untreated HCT-116 cell line. D: HCT-116 with cisplatin. E: LoVo cancer cell line without addition of drugs. F: The
percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.
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Figure 3 Comet assay data by using the Comet Score
software. The pink represent the DNA in nucleus, while the
orange the fragmented DNA. A: Control MCF-7 cell line. B: MCF-7 after
incubation with doxorubicin. C: The same cell line post-incubation with
melphalan. The percentage of DNA in tail has been reduced, indicating
the effect from the drugs.
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been observed especially in combination with cisplatin
(CDDP). Cisplatin binds to DNA to cause cross linking,
which leads to apoptosis; it is often combined with other
chemotherapy drugs in cancer treatment [15]. In breastcancer, an anthracycline antibiotic is also used; it inhibits
the enzyme topoisomerase II, thus inhibiting transcription.
Doxorubicin (trade name Adriamycin) is often used in
chemotherapy combinations such as AC (doxorubicin-
cytoxan), ATC (doxorubicin-cyclophosphamide-Taxol), AT
(doxorubicin-taxotere), and FAC (fluorouracil-doxorubicin-
cytoxan) [16,17]. Dose-limiting side effects, such as myelo-
suppression and cardiotoxicity, have been reported after
treatment with doxorubicin [18]. Excluding side effects can
greatly improve healing of carcinomas. Recent studies have
indicated that MAP kinases play an important role in resist-
ance to treatment with doxorubicin, mechlorethamine,
paclitaxel and proteasome inhibitors [19].
Many techniques to predict chemotherapy response
are available. Assays based on PCR can show genes for
enzymes that affect metabolism of these drugs, and can
therefore indicate response to a given agent [20,21].
However, they predict response at a genomic level,
which often deviates significantly from protein and cellu-
lar levels. On the other hand, the study of a great num-
ber of proteins displays many restrictions. First, we need
high amounts of proteins, which mean a lot of genetic
material. Furthermore, the use of Western Blot technique is
intended for a limited number of proteins. Additionally,
the response to chemotherapy drugs is affected be many al-
leles (CYB2D6, CYP2C19, CYP3A4 etc.), so the study of all
them in most cases is expensive and time-consuming.
Other techniques are based on molecular imaging, such as
18 F-fluorodeoxyglucose-positron emission tomography
(18-FDG-PET) or magnetic resonance imaging (MRI) [22],
but these methods have common adverse effects. Both
techniques are non-invasive, however 18-FDG-PET in-
volves exposure to ionizing radiation and the MRI environ-
ment may cause harm in patients by using strong magnetic
fields and radiowaves. Comet assay require only a few of a
patient’s cells, which can be easily isolated from whole
blood. By administrating the chemotherapy agents and then
applying an electric field to the DNA, unfragmented DNA
moves slowly because it is too large, whereas fragmented
parts move faster because of their lighter molecular weight
and dense conformation. Unfragmented DNA is thus dis-
tributed in the nucleus - the comet’s “head” - and fragmen-
ted pieces in the “tail”. The comparative percentage of
DNA in a single cell’s “head” and ”tail” reflects the effect of
a drug on its DNA chains. These percentages are ascer-
tained from the assignment of the pixels in photographs of
the assay, as a percentage with no units [23]. By analyzing
the above data from many cells, the effect of a drug can be
determined. This method can be used also to study genetic
instability, or genotoxicity [24,25]. Comet assays can be
used to determine bladder cancer cell radiation as well as
radiosensitivity in other types of cancer [26].
This particular work contains numerous cancer cell
lines, which represent two widespread types of cancer.
Figure 4 Presentation of comet assay data by using a five-grade scale. The comets are classified according to extent of DNA in tail and a
value 0-4 is given (0: almost no DNA in tail, 4: almost the entire DNA in tail). By measuring 100 comets, an overall score between 0 and 400
arbitrary units is calculated. A: Treatment with cisplatin in colorectal cancer cell lines. B: Treatment with melphalan in breast cancer cell lines
C: Treatment with mechlorethamine in breast cancer cell lines D: Treatment with doxorubicin in breast cancer cell lines.
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were tested. Also there is a study of several most com-
mon chemotherapeutic drugs.
The experimental data demonstrated that personalized
treatment is essential in cancer treatment. The data from
colon cancer cell lines indicated that cisplatin does not
affect each cell line to the same grade. Also, in some
cases, like LoVo, the cisplatin is probably ineffective.
Between HCT-15 and LoVo, which both represent
colon adenocarcinoma, completely different data were
observed. However, it is remarkable that LoVo derived from
a metastatic tumour. Recent literature data, indicate that
cisplatin in combination with other agents is more effective
than monotherapy in this particular cell line [27].
Among the breast cancer cell lines, the T47D cells
carry receptors for a variety of steroids, while MCF-7
cells express oestrogen receptors. The variety between
these receptors may explain the different response to
chemotherapy. MDA-MB 231 established from a pleural
effusion of a 51 year old woman with metastatic breast
cancer, indicating that mechlorethamine might be more
effective in metastatic breast tumour.Comet assays are a sensitive means of detecting both
single strand and double strand DNA damage, using
only a few cells. Our results here reinforced the hetero-
geneity of cancer by showing how the effectiveness of
each drug varied in each cell line, even when derived
from the same cancer type. Potentially, comet assays
could allow physicians to evaluate patient response in
advance, thus avoiding inappropriate therapies with un-
desired effects. SCGE is a relatively quick versatile,
simple-to-perform technique with a few requirements.Conclusion
Tailor-made therapy is a promising theme in transla-
tional cancer research. However, identifying optimal
treatment for an individual patient can be difficult, time-
consuming and expensive. Here, we evaluated the
effectiveness of comet assays on four commonly used
chemotherapeutic drugs, and found that this technique
can predict responses of different cancers to the subject
drugs and generally to drugs with the same mechanisms
of action. Further studies with a wider variety of tumor
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utility of comet assays in selecting cancer treatments.
Methods
Cell lines
We used human breast cancer cell lines MCF-7, MDA-MB
231 and T47D, and colon cancer cell lines HCT-116,
HT55, HCT-15 and LoVo, which came from the European
Collection of Cell Cultures (ECACC - HPA cultures, UK).
Cells were cultured in 75 cm2 flasks (5520200; Orange
Scientific) at 37°C in a 5% CO2 atmosphere, in the rec-
ommended media supplemented with the appropriate
amount of heat-inactivated fetal bovine serum (Invitro-
gen, 10106-169, California) and 2 mM L-glutamine
(Sigma, G5792, Germany).
Drugs
According to literature data, the optimal concentration
of each drug varies by cell type and cancer type. Cells
were cultured in 12-well plates (3513, Corning) in differ-
ent concentrations (0.01-50 μM) for each drug. Their
viability was analyzed with propidium iodide staining
after 24 hrs of incubation (NucleoCounter® NC-100™,
Chemometec). Concentrations that were chosen for fur-
ther experiments were 0.1 μM for mechlorethamine
(122564, Sigma-Aldrich), 1 μM for melphalan (Μ2011,
Sigma-Aldrich), 1 μM for doxorubicin (D1515, Sigma-
Aldrich) and 1 μM for cisplatin (P4394, Sigma-Aldrich).
Comet Assay
Cells were divided into 25 cm2 flasks (5520100, Orange
Scientific), one for each drug and one with no drug
added. After 24 hrs of incubation, cells were detached by
trypsinization (Trypsin-0.25% EDTA, 25200-072; Invitro-
gen) and 20000 cells were used for single cell gel electro-
phoresis with IKZUS comet assay kit (0905-050-K,
IKZUS). Alkaline lysis of the cells was performed ac-
cording to manufacturer’s instructions. Slides were ob-
served under a UV microscope. Data were analyzed with
Comet Score software (TriTek Corp., USA).
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